, an outbreak of pertussis-like illness (incidence, 80 cases per 100 000 persons) occurred in Franklin County, Ohio. The majority of cases were identified by IS481-directed polymerase chain reaction (PCR), which does not differentiate among Bordetella species. We sought to determine outbreak etiology and epidemiologic characteristics.
The incidence of reported pertussis has increased in the United States despite widespread use of effective vaccines [1, 2] . Clinical presentation can include cough illness persisting 4-8 weeks or longer, paroxysms, posttussive vomiting, and inspiratory whoop. Bordetella pertussis is the primary pathogen associated with the disease, and Bordetella parapertussis can produce illness resembling mild or moderate pertussis [3] . Additionally, Bordetella bronchiseptica and Bordetella holmesii have been detected in respiratory tracts of patients with pertussis-like symptoms. Bordetella bronchiseptica primarily infects nonhuman hosts; however, it has been reported to cause opportunistic upper respiratory tract infections among immunocompromised persons [4] . Bordetella holmesii was originally identified as a rare cause of bacteremia, predominantly among young adults with hyposplenism [5] [6] [7] [8] [9] , but has been isolated from respiratory specimens obtained from otherwise healthy persons with pertussis-like illness [6, [10] [11] [12] [13] [14] [15] .
Clinical diagnosis of pertussis can be difficult because infection can present with nonspecific signs or symptoms. Laboratory testing typically relies on testing of nasopharyngeal (NP) secretions by real-time polymerase chain reaction (PCR) assays that target various nucleic acid sequences. The insertion sequence IS481 is often targeted for clinical diagnosis because 50-238 copies of IS481 are present per B. pertussis genome, which contributes to assay sensitivity [16, 17] ; however, 8-10 copies of IS481 are present per B. holmesii genome [18] and the sequence is detected in 1%-5% of B. bronchiseptica strains [19, 20] , potentially leading to incorrect diagnoses. Additional PCR targets can be used to improve specificity by differentiating among Bordetella species [17, [21] [22] [23] .
During May 2010-May 2011, an outbreak of pertussis-like illness occurred in Franklin County, Ohio (population approximately 1.15 million [24] ), which includes the city of Columbus. A majority of cases were classified on the basis of an IS481 PCR assay performed at a local hospital laboratory, and a limited number of B. pertussis isolates were obtained. We sought to describe outbreak epidemiologic characteristics, determine etiology, evaluate vaccination coverage among patients, and develop recommendations for prevention and control of future outbreaks.
METHODS

Case Ascertainment
We retrospectively searched the Ohio Disease Reporting System (ODRS) [25] to identify and classify illnesses among Franklin County residents reported to have had onset of pertussis-like illness during 9 May 2010-7 May 2011, a 52-week period centered at the week of highest incidence. Confirmed cases were either (1) cough of ≥14 days with at least 1 classical pertussis sign (ie, paroxysms, whoop, or posttussive vomiting) with a PCR result positive for a target present in B. pertussis, or (2) cough of ≥14 days with at least 1 classical pertussis sign with close contact to a patient with illness confirmed by either culture or PCR, or (3) a cough of any duration with isolation of B. pertussis. Probable cases were cough of ≥14 days with at least 1 classical pertussis sign, and without confirmation by culture or PCR or epidemiologic linkage to a lab-confirmed case [26] . Suspected cases were defined as cough of <14 days and at least 1 classical pertussis sign in either (1) a person with a PCR result positive for a target present in B. pertussis, or (2) a person with close contact to a patient with confirmed illness. For 32 cases where illness onset dates were unknown, we substituted the earliest of the following events in place of the date of illness onset as follows: diagnosis date, specimen collection date, or date reported to the Ohio Department of Health. In accordance with standard reporting procedures, patients or parents of patients were interviewed by local health department personnel, with the final interview occurring at least 14 days after cough onset. Coughs persisting beyond the final interview were not followed to resolution.
Epidemiologic Data Sources
We obtained demographic and clinical descriptions of patients from ODRS, population data from the 2009 US Census Bureau, National Center for Health Statistics Bridged-Race Population Estimates [24] , and immunization records from the Ohio Impact Statewide Immunization Information System and ODRS, which includes immunization records reported by healthcare providers, patients, and parents or guardians of patients. A tetanus-diphtheria-acellular pertussis (Tdap) vaccination was defined as a record of any pertussis-containing vaccination in a person aged ≥10 years. We examined Tdap records for adolescents aged 11-18 years, an age group for which the Advisory Committee on Immunization Practices recommends a single dose of Tdap [27] . Antibiotic administration records were obtained from ODRS, which combines clarithromycin and azithromycin therapy into a single group, thereby preventing individual analysis of either antibiotic.
Specimen Collection and Laboratory Testing
During 10-16 December 2010, we requested blood samples from Franklin County residents aged 10-57 years who were reported to have onset of pertussis during 25 October-27 November, 2010. To detect recent infection by B. pertussis, we tested 14 serum specimens at the Centers for Disease Control and Prevention (CDC) Pertussis and Diphtheria Laboratory by using a single-point indirect enzyme-linked immunosorbent assay (ELISA) for detection of immunoglobulin G (IgG) antibodies against PT [28] ; specimens with anti-PT IgG concentrations of ≥94 IU/mL were considered to be seropositive [28, 29] . IS481 results obtained from NP specimens submitted to the Molecular Diagnostics Laboratory at Nationwide Children's Hospital (NCH) in Columbus, Ohio, for routine clinical testing for B. pertussis and B. parapertussis (see PCR assay methods below) were available for 10 of 14 patients who had blood collected for anti-PT IgG serology. In addition, residual NP samples archived at NCH were available from 6 of these 10 patients.
These 6 NP samples were tested at the CDC using 2 PCR assays. The first was a multiplex assay targeting IS481 (detected in B. pertussis, B. holmesii, and in a small percentage of B. bronchiseptica isolates), hIS1001 (detected in B. holmesii only), and pIS1001 (detected in B. parapertussis and infrequently in B. bronchiseptica), and the second was a singleplex assay targeting ptxS1 (detected in B. pertussis, B. parapertussis, and B. bronchiseptica) [23] . The 6 samples were also tested by NCH in 3 separate PCR assays. These included a multiplex assay for IS481 and BparaIS1001 (specific for B. parapertussis), Abbreviations: bp, base pairs; F, forward primer; R, reverse primer; P, probe. a Probe 5′ end labeled with 6-carboxyfluorescein (FAM) and 3′ end labeled with 6-carboxytetramethylrhoda mine (TAMRA).
b Probe 5′ end labeled with 4,7,2′-trichloro-7′-phenyl-6-carboxyfluorescein (VIC) and 3′ end labeled TAMRA. a singleplex assay targeting the ptxA-Pr sequence (detected in B. pertussis and at high bacterial concentrations in B. parapertussis), and another singleplex assay targeting BholIS1001 (specific for B. holmesii) ( Table 1) . Additionally, a convenience sample of 298 IS481-positive/BparaIS1001-negative NP swab specimens collected and archived (−70°C) during the outbreak interval were tested by NCH in their ptxA-Pr and BholIS1001 PCR assays.
Statistical Analyses
We analyzed data by using SAS, version 9. 
where PCV = proportion of cases vaccinated and PPV = proportion of population vaccinated [30] , with Wald 95% confidence limits calculated by using logistic regression with only a constant (intercept) and the logit of PPV as the offset. We set PPV at 70% for Tdap VE calculations; although precise Tdap coverage among adolescents aged 11-18 years in Franklin County is unknown, the 2011 National Immunization Survey reported Tdap coverage among Ohio adolescents aged 13-17 years to be 72.7% (95% confidence interval [CI], 67.2%-78.2%) [31] . Significance was determined at α = .05.
Institutional Review Board Approval
Components of this study performed by the CDC were determined to be public health practice by the CDC and were exempted from institutional review board (IRB) review. Archival and testing of NP specimens was approved by NCH's IRB (IRB11-00096).
RESULTS
Outbreak Description
Among residents of Franklin County, 645 confirmed, 29 probable, and 244 suspected cases of pertussis were reported with onset 9 May 2010-7 May 2011 ( Figure 1) ; illness occurrence was highest during 24 September-12 November 2010. Overall incidence was 80 cases per 100 000 persons; highest incidences were reported among infants aged <1 year (619 cases per 100 000 persons) and among persons of Hispanic ethnicity (151 cases per 100 000 persons) ( Table 2) . No pertussisrelated deaths were reported. Paroxysmal cough was the most commonly reported clinical sign (82% of patients), followed by posttussive vomiting (42%) and whoop (20%); 81% had cough of ≥14 days; 18 (2%) patients were hospitalized (Table 2) . Among 645 confirmed cases, 62% were classified on the basis of a positive PCR result and lacked reported contact with a confirmed case; 20% had a positive PCR result and reported close contact with a confirmed case; and 18% lacked PCR confirmation and were classified on the basis of an epidemiologic link to a confirmed case. No positive cultures were reported.
Serologic Investigation
Among 14 (5 suspected and 9 confirmed) serologically tested patients (response rate 14%, Table 3 ), IS481 PCR results were available for 10; PCR data were obtained from NP specimens IS481, negative for ptxA-Pr, and positive for BholIS1001, indicating presence of B. holmesii and not B. pertussis DNA (Table 3 , cases 1-3). These assays also identified 2 patients likely to have had B. pertussis without B. holmesii, and 1 patient likely to have had both (Table 3 ; cases 4, 5, and 10, respectively). Similar results were obtained from aliquots of these NP specimens tested by the CDC in a blinded fashion by using a multiplex and a singleplex PCR able to differentiate among Bordetella species, including B. parapertussis (Table 3) . No patients with B. parapertussis were identified.
Comparison of B. holmesii With B. pertussis
Among the convenience sample of 298 IS481-positive NP swabs, we identified specific Bordetella species in 164, 48 (29%) were positive for B. holmesii (BholIS1001positive only), 112 (68%) were positive for B. pertussis ( ptxA-Pr positive only), and 4 (2%) were positive for both B. holmesii and B. pertussis (Figure 2 ). Among 48 patients with B. holmesii infections, 30 (63%) were aged 11-18 years and 13 (27%) were aged 15-18 years, compared with 39 (35%) of 112 patients with B. pertussis who were aged 11-18 years and 3 (3%) aged 15-18 years, excluding patients with evidence of both pathogens (P = .001 for 11-18 years). Among 70 IS481-positive adolescents aged 11-18 years who were identified as having evidence of a specific Bordetella species, 30 (43%) were positive for B. holmesii only, 39 (56%) were positive for B. pertussis only, and 1 (1%) was positive for both. Infants aged <1 year comprised a similar proportion of both illness types (15% of patients with B. holmesii, and 13% of patients with B. pertussis; P = .72) (Figure 3 ). Overall age distribution of patients tested for species-specific PCR targets differs from those not tested for species-specific PCR targets (P < .0001). However, when the comparison was restricted to patients aged <24 years (comprising 89% of outbreak patients), the age distributions were similar (P = .54). Among 48 patients with B. holmesii (excluding B. pertussis or B. holmesii coinfections), 42 (88%) had paroxysms, 21 (44%) had posttussive vomiting, 11 (23%) had whoop, and 42 (88%) had a cough duration of ≥14 days. The frequencies of these clinical signs were similar among patients with B.
pertussis infections, and no statistical differences were detected within the age strata examined (<1 year, 1-10 years, and 11-18 years) ( Table 4 ). All B. pertussis-and B. holmesii-positive patients received antibiotics. Clarithromycin or azithromycin was administered to 45 (94%) patients with B. holmesii and 103 (92%) patients with B. pertussis. Following antibiotic administration, coughing persisted longer among patients with B. pertussis, compared with B. holmesii (P = .01) (Figure 4 ). We found no association between patient age and time from antibiotic administration to cough cessation (P = .45). Tdap receipt was confirmed for 18 (60%) and 17 (44%) patients aged 11-18 years with B. holmesii and B. pertussis infection, respectively (Table 5) . We were unable to obtain immunization records for 1 B. holmesii patient and 4 B. pertussis patients. Although Tdap coverage was higher among patients with B. holmesii, compared with B. pertussis, this difference was not significant (P = .18). Estimated effectiveness against B. holmesii was 36% (95% CI, −33% to 69%), compared with 67% for B. pertussis (95% CI, 38%-82% (Table 5) .
DISCUSSION
We report the first documented mixed outbreak of B. pertussis with B. holmesii, with nearly two-thirds of B. holmesii cases aged 11-18 years. A majority of cases were diagnosed and reported as pertussis on the basis of clinical presentations and IS481 PCR positivity. Although this methodology is widely practiced, these criteria are insufficient for differentiation among Bordetella species. Some misclassification of B. holmesii as B. pertussis as a result of a highly sensitive assay may be clinically acceptable [21, 32] . Until recently, data suggested that B. holmesii prevalence was low, even among patients with classic pertussis symptoms. For example, a study of 12 727 NP specimens obtained from persons suspected of having pertussis during 1994-1998 yielded 7% B. pertussis isolates and only 0.26% B. holmesii isolates [10] , implicating B. holmesii for a small proportion of pertussis-like illnesses. Moreover, a review of 11 319 NP swabs obtained during 1992-2003 from Finnish and Dutch patients suspected of having pertussis produced no evidence of B. holmesii DNA [21] , further indicating that prevalence of B. holmesii might be low. However, a study of 177 NP specimens obtained during 2009-2010 from French patients suspected of having pertussis revealed B. holmesii DNA among 20% [14] , a result similar to our finding of B. holmesii among 17% of IS481-positive persons suspected of having pertussis (including 4 coinfections of B. holmesii with B. pertussis).
These results might be limited by sampling methodology, sample size, incomplete immunization reporting, presence of inconclusive samples (45% of 298 samples tested were positive for IS481, and negative for both species-specific PCR targets), and potentially differing sensitivities of ptxA-Pr and BholIS1001-based assays. Among patients with B. holmesii infections, 51% had cough at the final interview, compared with 77% of those with B. pertussis infections; thus, cough durations and differences in cough durations between etiologic categories are likely underestimated. Our finding that patients with B. holmesii were older than those with B. pertussis is consistent with previous reports that described highest B. holmesii incidence among adolescents or adults [10, 14] . Factors contributing to the higher proportion of B. holmesii among adolescents are unknown and might include age-dependent clinical presentation, transmission-related factors, or other unknown causes. Because our data are limited to the outbreak period in Franklin County, we are unable to describe the larger temporal or geographic features of B. holmesii incidence. In the setting of a resurgence of pertussis, with strong evidence of widespread transmission of B. pertussis, the relative contribution of B. holmesii to the total burden of reported pertussis could be small, but enhanced surveillance is necessary to elucidate the epidemiological characteristics of B. holmesii.
In addition to B. pertussis and B. holmesii, B. parapertussis circulated during the outbreak period. Among all nasopharyngeal specimens submitted to NCH for testing for Bordetella species during 9 May 2010-8 May 2011, 7.5% were positive for IS481, and 1.4% were positive for B. parapertussis BparaIS1001. Specimens were obtained predominantly (but not entirely) from patients located in the outbreak locale. Culture findings were consistent with PCR results, further validating these data (M. Marcon, personal communication, e-mail, July 2012). Cough illness among persons with B. holmesii might be caused by another etiology, with B. holmesii acting as a superinfecting agent or a subclinical colonizer. Carriage of B. holmesii among asymptomatic persons is unknown, and understanding of prevalence could aid in evaluation of these hypotheses [10] . After azithromycin or clarithromycin administration in this study, cough illness among patients with B. holmesii resolved more quickly than cough among persons with B. pertussis; PT, which is lacking in B. holmesii, might contribute to the relative recalcitrance of cough among patients with B. pertussis. Moreover, antimicrobial susceptibility testing of 15 B. holmesii isolates obtained from patients in the outbreak locale showed that most isolates were susceptible to azithromycin doses as low as 0.12 µg/mL (M. Marcon, personal communication); B. pertussis isolates were susceptible to lower doses of azithromycin. The apparent effectiveness of these antibiotics supports the probable bacterial etiology of cough among these patients, and these findings suggest that it would be reasonable for healthcare providers to apply standard pertussis care for either etiology.
Although differentiation might be unnecessary for treatment decisions, epidemiologic value is relevant in distinguishing among Bordetella species. Improved specificity would advance our understanding of burdens from B. pertussis and B. holmesii, reduce concerns arising from apparent vaccine failures after misdiagnosis, and might provide information on which vaccine-based outbreak response strategies can be based. Vaccinations remain important for prevention and control of pertussis, and vaccination campaigns should continue despite pertussis-like illness among certain vaccinated persons. Although a majority of pertussis cases in the United States are diagnosed at clinical laboratories where multitarget PCR might not be feasible, limited multitarget PCR capacity, especially among public health laboratories, is important for pertussis outbreak investigations and surveillance.
Notes
